A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus (CR059101)

A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

Primary Objectives:

•To evaluate the safety and tolerability of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059）in Chinese subjects with T2DM.

Secondary Objectives:

• To characterize the pharmacokinetic (PK) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059） in Chinese subjects with T2DM;
• To characterize the pharmacodynamic (PD) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059） in Chinese subjects with T2DM;
• To evaluate the immunogenicity of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059） in Chinese subjects with T2DM;

Participants :

Diagnosed with T2DM for at least 3 months but less than 5 years, according to the Chinese Diabetes Society's diagnostic criteria

Study Overview

• Status: Recruiting
• Conditions: T2DM
• Intervention / Treatment: Drug: Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））

Detailed Description

This is a single-center, open-label, single ascending dose study designed to evaluate the safety, tolerability, PK, PD, and immunogenicity of Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）in Chinese subjects with T2DM. It is planned to enroll 6-9 subjects.The study includes three dose cohorts (low, medium, high: 4 μg/kg, 8 μg/kg, 12 μg/kg). Each cohort plans to enroll 2-3 T2DM subjects. A single dose will be administered, with subjects observed in-hospital for at least 7 days.

• Study Type: Interventional
• Enrollment (Estimated): 9
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Hongwei Jiang, PhD Supervisor; Phone Number: 0379-69823582; Email: jianghw@haust.edu.cn

Study Locations

• China
  • Henan
    • Luoyang, Henan, China, 310015
      • Recruiting
      • The First Affiliated Hospital of Henan University of Science and Technology
      • Contact: Hongwei Jiang, Professor; Phone Number: 0379-69823582; Email: jianghw@haust.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Chinese male or female， 18≤age≤-65 years .
• Diagnosed with T2DM for at least 3 months but less than 5 years, according to the Chinese Diabetes Society's "Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2024 Edition)" diagnostic criteria.
• Patients who have failed treatment with diet and exercise alone, or metformin monotherapy, or a stable regimen for 12 weeks of metformin (dose ≥1500 mg/day or maximum tolerated dose ≥1000 mg/day) combined with one of the following oral antidiabetic drugs (or their fixed-dose combinations): sulfonylureas, glinides, alpha-glucosidase inhibitors, SGLT2 inhibitors, or thiazolidinediones (at ≥1/2 the maximum approved dose, or the recommended minimum maintenance dose for SGLT2 inhibitors e.g., empagliflozin 10mg, canagliflozin 100mg). Fasting Plasma Glucose (FPG) must be <13.0 mmol/L, and 7.5%≤HbA1c ≤ 10.0%.
• 18.5 kg/m²≤Body Mass Index (BMI) ≤40.0 kg/m² at screening and enrollment
• Subjects have no pregnancy plan from screening until 3 months after the last dose and are willing to use at least one effective method of contraception during the entire trial period until 3 months after the last dose.
• Able to understand and willing to sign the informed consent form, and fully understand the trial content, procedures, and potential adverse reactions.
• Able to complete the trial according to the protocol requirements.

Exclusion Criteria:

• Diagnosis of type 1 diabetes, diabetes due to pancreatic injury, or specific types of diabetes due to other diseases (e.g., acromegaly or Cushing's syndrome).
• History of acute diabetic complications, such as ketoacidosis or hyperosmolar coma, within 6 months before screening.
• Presence of severe chronic diabetic complications (e.g., proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within 6 months before screening, deemed by the investigator as unsuitable for participation.
• Allergic constitution (allergy to ≥2 types of drugs or foods) or keloid tendency, or clear history of drug allergy, or investigator suspects potential allergy to the investigational product or its components or similar drugs.
• Fasting plasma glucose <3.9 mmol/L at screening or before enrollment, and/or history of ≥2 episodes of severe hypoglycemia or recurrent symptomatic hypoglycemia within 6 months before screening.
• History or presence of Cushing's syndrome, polycystic ovary syndrome, or other hereditary endocrine diseases, or obesity secondary to factors such as hormones.
• Use of weight-control medications or weight-loss surgery within 3 months before screening, or weight fluctuation exceeding 5% within 3 months.
• Clinically significant abnormal TSH, FT3, or FT4 at screening, or previous diagnosis of thyroid dysfunction, deemed unsuitable by the investigator.
• Personal or family history of multiple endocrine neoplasia type 2; personal or family history of medullary thyroid carcinoma; or thyroid nodules classified as C-TIRADS category 4 or higher on ultrasound.
• History or presence of malignant tumors (except cured basal cell carcinoma or cervical carcinoma in situ).
• History of thrombotic diseases (e.g., deep vein thrombosis, pulmonary embolism, stroke), known bleeding diathesis or coagulation dysfunction, major thrombotic event within 6 months, or any coagulation parameter ≥1.5x ULN, or clinically significant abnormal coagulation function deemed unsuitable by the investigator.
• Long-term use (over 1 month) or current use of anticoagulants (e.g., warfarin, rivaroxaban, dabigatran) or antiplatelet drugs (e.g., aspirin, clopidogrel) before screening.
• Diagnosis of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to acute stroke, transient ischemic attack (TIA), acute coronary syndrome, coronary heart disease, heart failure, arrhythmia requiring treatment, etc.
• History of gout or gout attack within 6 months before screening or before enrollment.
• Untreated or poorly controlled hypertension (systolic BP >160 mmHg and/or diastolic BP >100 mmHg) at screening or before enrollment. Patients on antihypertensive therapy must have a stable regimen and dose for 1 month. If BP criteria are not met at screening/enrollment, one re-test is allowed. Exclusion if both readings fail.
• Heart rate at rest (after at least 10 min) <50 bpm or >100 bpm at screening or before enrollment. One re-test is allowed. Exclusion if both readings fail.
• PR interval >210 ms and/or QRS complex duration >120 ms, and/or QTcF >450 ms at rest at screening or before enrollment. If criteria not met, repeat ECG twice on the same day; use the average of 3 measurements for judgment.
• History of clinically significant chronic or acute exacerbating respiratory diseases, including but not limited to asthma, COPD (excluding obstructive sleep apnea).
• History of severe gastrointestinal disease (e.g., active ulcer, gastroparesis, pyloric obstruction, inflammatory bowel disease) within 6 months before screening or before enrollment, or gastrointestinal surgery, or long-term use of drugs directly affecting GI motility due to chronic GI disease, deemed unsuitable by the investigator.
• Severe renal disease or estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73m² (CKD-EPI formula) at screening or before enrollment.
• Serum amylase or lipase >3x Upper Limit of Normal (ULN) at screening or before enrollment, or history/known chronic pancreatitis, acute pancreatitis, pancreatic injury.
• History of cholelithiasis, acute or chronic cholecystitis (except those with no residual biliary stones post-treatment or post-cholecystectomy without sequelae, deemed eligible by the investigator).
• Severe dyslipidemia, with LDL-C ≥4.40 mmol/L or triglycerides (TG) ≥5.65 mmol/L at screening or before enrollment. If on lipid-lowering therapy, regimen and dose must be stable for 1 month.
• Clear history of psychiatric disorders (e.g., depression, schizophrenia, bipolar disorder) within 2 years before screening.
• Major surgery within 1 month before screening, or presence of severe infection or active inflammation.
• History of blood donation >400 mL, transfusion, or blood loss within 90 days before screening or before enrollment.
• Any of the following laboratory abnormalities at screening or before enrollment: 1. ALT or AST >2x ULN; 2. Total Bilirubin >1.5x ULN; 3. Calcitonin ≥35 pg/mL; 4. Hemoglobin <110 g/L (female) or <120 g/L (male); 5. Clinically significant abnormal platelet count; 6. Clinically significant abnormal white blood cell or neutrophil count;
• Use of any approved or unapproved weight-affecting drugs or products within 3 months before screening, including but not limited to orlistat, phentermine-topiramate, naltrexone-bupropion, systemic corticosteroids, antidepressants (SSRIs, SNRIs, tricyclics, tetracyclics), antipsychotics/sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, lithium), etc.
• Use of any DPP-4 inhibitor, or GLP-1, GIP, GCG receptor agonists, or FGF-21 within 6 months before screening.
• History of bariatric surgery (except liposuction/abdominoplasty >1 year prior).
• Participation in any drug or medical device clinical trial within 3 months before screening or before enrollment (except screen failures).
• Positive serology for HBsAg, anti-HCV antibody, anti-TP antibody, or anti-HIV antibody at screening.
• History of drug abuse and/or alcoholism (weekly alcohol intake >14 units) within 6 months before screening
• Positive urine drug screen or alcohol breath test at screening.
• Pregnant or lactating females, or subjects using oral contraceptives.
• Intolerance to venipuncture or history of needle syncope, blood-injury syncope.
• Any other physiological, psychological, or situational condition deemed by the investigator as unsuitable for trial participation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059）	Drug: Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））; use one dose per person

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events (TEAEs)	Adverse events (AEs) / Serious adverse events (SAEs) will be collected via: Laboratory tests (including complete blood count, blood biochemistry, glucagon, lipase, amylase, urinalysis, coagulation function, high-sensitivity C-reactive protein, inflammatory factors); Vital signs (blood pressure, pulse rate, body temperature, respiration); Physical examinations (including skin, mucous membranes, lymph nodes, head and neck, chest, abdomen, spine and extremities, and musculoskeletal tissues); 12-lead electrocardiogram (12-lead ECG, including PR interval, QRS duration, QTcF interval); Abnormalities observed by the investigator; Subject-reported complaints.	From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit(Day 36)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic	Cmax	From the first dose (Day 1 ) of study drug until Day 36
Pharmacokinetic	Tmax	From the first dose (Day 1 ) of study drug until Day 36
Pharmacokinetic	Area under the concentration-time curve from time zero to the time of the last quantifiable concentration（AUC0-last）	From the first dose (Day 1 ) of study drug until Day 36
Pharmacokinetic	Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC0-inf)	From the first dose (Day 1 ) of study drug until Day 36
Pharmacokinetic	Apparent Clearance (CL/F)	From the first dose (Day 1 ) of study drug until Day 36
Pharmacokinetic	Apparent Volume of Distribution (VZ/F)	From the first dose (Day 1 ) of study drug until Day 36
Pharmacokinetic	Elimination Half-Life (t1/2)	From the first dose (Day 1 ) of study drug until Day 36
Anti-Drug Antibodies	ADA positivity rate	Day 1 (first dosing day)、Day 15、Day 29
Pharmacodynamics	Plasma Glucose	From the baseline(Day 2)until completion of the post treatment follow-up visit (Day 36)(Day 1 :first dosing day)
Pharmacodynamics	Serum C-peptide	From the baseline(Day 2)until completion of the post treatment follow-up visit(Day 36)(Day 1 :first dosing day)
Pharmacodynamics	Serum insulin	From the baseline(Day 2)until completion of the post treatment follow-up visit(Day 36)(Day 1 :first dosing day)
Anti-Drug Antibodies	ADA titer	Day 1(first dosing day)、Day 15、Day 29

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
• Collaborators: PegBio Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2026
• Primary Completion (Estimated): August 31, 2026
• Study Completion (Estimated): August 31, 2026

Study Registration Dates

• First Submitted: December 29, 2025
• First Submitted That Met QC Criteria: January 15, 2026
• First Posted (Actual): January 16, 2026

Study Record Updates

• Last Update Posted (Actual): April 6, 2026
• Last Update Submitted That Met QC Criteria: March 31, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: CR059101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: underlie the results reported in this study-including demographics, baseline characteristics, efficacy, and safety data-will be shared with researchers who provide a methodologically sound proposal, starting 6 months after publication of the primary outcomes in a peer-reviewed journal.
• IPD Sharing Time Frame: Starting 6 months after publication of the primary outcomes in a peer-reviewed journal.The data will remain available for access for a period of 24 months.
• IPD Sharing Access Criteria: Access is restricted to academic researchers for non-commercial, scientific purposes
• IPD Sharing Supporting Information Type: ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No